Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,963 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,963 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Open enrollment, early-phase tilt
HIV Infections has 615 registered US clinical trials, 56 of them open to new participants right now, about 9% of the total.
- 56
- recruiting participants now
- 9%
- of trials open to enrollment
- 92
- in Phase 3-4 (later-stage)
- 195
- top sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Corpus placement: #7 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 8 of 13
Phase II Study of Zidovudine and Recombinant Alpha-2A Interferon in the Treatment of Patients With AIDS-Associated Kaposi's Sarcoma
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000687
A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001081
Curb, Alter, Lower, or Manage Stress in HIV: CALMS-HIV
National Center for Complementary and Integrative Health (NCCIH)
NCT00057538
Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
Argos Therapeutics
NCT00672191
Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates
ViiV Healthcare
NCT02578277
Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA
National Institute of Allergy and Infectious Diseases (NIAID)
NCT03181789
Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women
Charles Drew University of Medicine and Science
NCT00004400
A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00038272
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
Gilead Sciences
NCT01967940
Preliminary Study of Safety and Efficacy of Policosanol
Rush University Medical Center
NCT00312923
Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00084149
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000819
Natural History Study of HIV Acquired in Infancy or Childhood
National Cancer Institute (NCI)
NCT00924365
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
Friends Research Institute
NCT00856323
Buprenorphine and Integrated HIV Care
Yale University
NCT00317460
Bioequivalency Study of Zidovudine Under Fasting Conditions
Roxane Laboratories
NCT00602550
Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01780831
Planning a Multi-Level Intervention to Reduce Substance Use Stigma in HIV Prevention and Care
Wayne State University
NCT05925374
An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000709
Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With Amprenavir, Nelfinavir, or Saquinavir
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001133
Marijuana for HIV-Related Peripheral Neuropathy
Center for Medicinal Cannabis Research
NCT00046722
Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin
ViiV Healthcare
NCT04563845
Adding New Drugs for HIV Infected Patients Failing Current Therapy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00031044
Acupuncture/Moxibustion for Peripheral Neuropathy in HIV
National Center for Complementary and Integrative Health (NCCIH)
NCT00317291
Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients
AJI Pharma U
NCT00002098
A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000907
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00119379
The Safety and Efficacy of Clindamycin and Primaquine in the Treatment of Mild - Moderate Pneumocystis Carinii Pneumonia in Patients With AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000717
Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00574600
A Study of 141W94 in Combination With Other Anti-HIV Drugs
Glaxo Wellcome
NCT00002372
Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV
University of Alabama at Birmingham
NCT04193605
A Phase I Randomized Dose/Formulation Comparison Study of SC-52151
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000806
Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001019
Outcomes of Anti-HIV Therapy During Early HIV Infection
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001093
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults
International AIDS Vaccine Initiative
NCT04224701
Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02356302
Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01571960
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000822
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000703
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
Incyte Corporation
NCT00393120
Aerosols in the Treatment of Pneumocystis Pneumonia: A Pilot Study Quantitating the Deposition of Aerosolized Pentamidine as Delivered in ACTG 040 and Comparing Its Toxicity With Parenteral Pentamidine Therapy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000722
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000778
Exercise and Pioglitazone for HIV-Metabolic Syndromes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00639457
Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00099684
The Treatment of Insomnia in Patients With HIV Disease
Duke University
NCT00465972
Vitamin D Dose Finding Study
Children's Hospital of Philadelphia
NCT01092338
Effects of Creatine and Resistance Exercise Training in People With HIV Infection
National Center for Complementary and Integrative Health (NCCIH)
NCT00484627
Treatment for Depression Among HIV-Infected Youth
University of North Carolina, Chapel Hill
NCT01049789
A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy
Harbor Therapeutics
NCT00002422
A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000710
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for HIV Infections right now
56 recruiting of 615 indexed (9% open).
Phase mix: 92 late (III/IV) vs 266 early (I/II) (early-phase heavy).
Top sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (195 trials), 9 others listed. 50 shown below, recruiting first. #7 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for HIV Infections?
PlainTrial tracks 615 US clinical trials for HIV Infections, of which 56 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for HIV Infections?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.